Evaxion Biotech A/S ADR (EVAX) Stock Price, Quote & News

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 31 31 97 53

Website: evaxion.ai

Address:

Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark

AndreaRR Oct. 4 at 10:33 PM

$EVAX

0 · Reply

chitransh1982 Oct. 4 at 3:27 PM

$EVAX $9 by Oct. 30th

0 · Reply

MT25 Oct. 4 at 7:47 AM

$EVAX Next week we will hit $7+ After 17 October 20+ Why? They won’t miss with so many presentations… In the coming week EVAX is at BioTechX Europe, taking place in Basel next week from October 6-8. It seems pretty obvious that an updated presentation of EVAX AI-Immunology™ platform is a wise step leeaning up the biggest event of EVAX history whenEvaxion will present new biomarker and immune data stemming from the ongoing phase 2 trial with EVX-01. The two-year clinical efficacy data from the trial will, as earlier announced, be presented in an oral presentation at the ESMO 2025 congress on October 17, 2025. Both datasets will add to an already strong data package for EVX-01, which includes convincing one-year interim data from the phase 2 trial.

1 · Reply

Tigerz11 Oct. 3 at 8:43 PM

$EVAX $20

1 · Reply

OTCshithead Oct. 3 at 8:41 PM

$EVAX The gift that keeps on giving 🙏 congrats bulls $SNGX Holding ⏳️ $GME holding⏳️ $KIDZ holding ⏳️

1 · Reply

invest01 Oct. 3 at 6:29 PM

$EVAX It is becoming increasingly clear that we are only days away from reaching the $15–18 range per share.

0 · Reply

sdavey1234 Oct. 3 at 5:54 PM

$EVAX If this presentation is positive which many believe it will be given the recent investment.. this stock will 200-300% that day in my opinion. Not financial advice 🥳

0 · Reply

PharmaExpert Oct. 3 at 5:50 PM

$AKBA, $ANRO, $NEUP, $EVAX, $CASI 🔥🔥🔥🔥🔥

1 · Reply

PDXKing Oct. 3 at 5:23 PM

So far, $EVAX is doing great for the day, up 10% with a little over 500k in volume. If this goes to a million or two in volume, it will 2x. I am hoping for 10x. $INTC $TSLA $SPY $EVAX

0 · Reply

johnthegreatz Oct. 3 at 5:05 PM

$EVAX 50k shares in, this is a good day

0 · Reply

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Sep 25, 2025, 11:07 AM EDT - 9 days ago

Evaxion A/S - Special Call

Sep 25, 2025, 7:00 AM EDT - 9 days ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Aug 19, 2025, 3:29 PM EDT - 6 weeks ago

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 8:00 AM EDT - 7 weeks ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Jul 25, 2025, 9:00 AM EDT - 2 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 11, 2025, 8:00 AM EDT - 3 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 1, 2025, 8:30 AM EDT - 3 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jun 25, 2025, 8:00 AM EDT - 3 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 3, 2025, 9:15 AM EDT - 4 months ago

Evaxion receives grant funding to design new polio vaccine

May 27, 2025, 10:43 AM EDT - 4 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 7:30 AM EDT - 4 months ago

Evaxion announces business update and first quarter 2025 financial results

May 26, 2025, 8:47 AM EDT - 4 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 23, 2025, 8:00 AM EDT - 4 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 22, 2025, 8:00 AM EDT - 4 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Apr 28, 2025, 8:00 AM EDT - 5 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 10, 2025, 8:00 AM EDT - 6 months ago

Evaxion to present at World Vaccine Congress

Apr 1, 2025, 11:21 AM EDT - 6 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:00 AM EDT - 6 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 25, 2025, 4:30 PM EDT - 6 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Feb 25, 2025, 8:00 AM EST - 7 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Jan 31, 2025, 4:05 PM EST - 8 months ago

Evaxion announces closing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 8 months ago

Evaxion announces pricing of $10.8 million public offering

Jan 28, 2025, 8:15 AM EST - 8 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 14, 2025, 4:05 PM EST - 9 months ago

Evaxion announces completion of ADS ratio change

Jan 10, 2025, 8:00 AM EST - 9 months ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 9 months ago

Evaxion announces plan to implement ADS ratio change

Nov 12, 2024, 8:00 AM EST - 11 months ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Sep 26, 2024, 10:53 AM EDT - 1 year ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion significantly expands vaccine development collaboration with MSD

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Aug 14, 2024, 11:43 AM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 7:27 AM EDT - 1 year ago

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Jul 3, 2024, 8:05 AM EDT - 1 year ago

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Jun 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Jun 17, 2024, 8:44 AM EDT - 1 year ago

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

May 28, 2024, 8:21 AM EDT - 1 year ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

May 23, 2024, 5:00 PM EDT - 1 year ago

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

May 10, 2024, 5:00 PM EDT - 1 year ago

Evaxion Receives Nasdaq Notification

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Apr 2, 2024, 2:10 PM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

AndreaRR Oct. 4 at 10:33 PM

$EVAX

0 · Reply

chitransh1982 Oct. 4 at 3:27 PM

$EVAX $9 by Oct. 30th

0 · Reply

MT25 Oct. 4 at 7:47 AM

1 · Reply

Tigerz11 Oct. 3 at 8:43 PM

$EVAX $20

1 · Reply

OTCshithead Oct. 3 at 8:41 PM

$EVAX The gift that keeps on giving 🙏 congrats bulls $SNGX Holding ⏳️ $GME holding⏳️ $KIDZ holding ⏳️

1 · Reply

invest01 Oct. 3 at 6:29 PM

$EVAX It is becoming increasingly clear that we are only days away from reaching the $15–18 range per share.

0 · Reply

sdavey1234 Oct. 3 at 5:54 PM

$EVAX If this presentation is positive which many believe it will be given the recent investment.. this stock will 200-300% that day in my opinion. Not financial advice 🥳

0 · Reply

PharmaExpert Oct. 3 at 5:50 PM

$AKBA, $ANRO, $NEUP, $EVAX, $CASI 🔥🔥🔥🔥🔥

1 · Reply

PDXKing Oct. 3 at 5:23 PM

So far, $EVAX is doing great for the day, up 10% with a little over 500k in volume. If this goes to a million or two in volume, it will 2x. I am hoping for 10x. $INTC $TSLA $SPY $EVAX

0 · Reply

johnthegreatz Oct. 3 at 5:05 PM

$EVAX 50k shares in, this is a good day

0 · Reply

apkjiv88 Oct. 3 at 4:35 PM

$EVAX guessing you dont present that much unless you have something to say, or sell 🤔

0 · Reply

shibimo Oct. 3 at 4:06 PM

$EVAX i think big whales came into the play. Let go😍

0 · Reply

saunderswe Oct. 3 at 3:32 PM

$EVAX Evaxion to present at several conferences during the second half of 2025 BiotechX Europe, October 6-8 - Basel World Vaccine Congress Europe, October 14-16 - Amsterdam European Society for Medical Oncology (ESMO) Congress 2025, October 17-21 - Berlin Society for Immunotherapy of Cancer (SITC) 2025, November 5-9 - National Harbor Vaccines Summit, November 13-15 - Boston NextGen Omics, November 13-14 - London

0 · Reply

prismmarketview Oct. 3 at 3:27 PM

(NASDAQ: $EVAX), Evaxion will present new EVX-01 biomarker and two-year efficacy data at SITC and ESMO 2025. Interim results show a strong 69% ORR for advanced melanoma. https://prismmarketview.com/evaxion-to-present-evx-01-biomarker-data-at-sitc-two-year-results-at-esmo/

0 · Reply

BackwardsBob Oct. 3 at 3:18 PM

$EVAX who is ready for volume to begin pushing us north

0 · Reply

BackwardsBob Oct. 3 at 1:54 PM

$EVAX $5+ here she comes

0 · Reply

PETER__BANKS Oct. 3 at 1:02 PM

$EVAX - Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

0 · Reply

Dingo2 Oct. 3 at 11:24 AM

$EVAX interesting action. Move up is stealthy; not many eyes on it yet

0 · Reply

NVDAMillionaire Oct. 3 at 7:34 AM

$EVAX Really good write-up that perfectly summarizes EVAX's present situation. So if you want to bring your EVAX knowledge up to date or just discover EVAX, this is required reading. https://beyondspx.com/quote/EVAX/analysis/evaxion-s-ai-powered-momentum-strategic-partnerships-and-pipeline-catalysts-drive-future-value-nasdaq-evax

0 · Reply

Manwiththeplan Oct. 3 at 7:33 AM

$EVAX they try to keep this down pre and post market. They cannot fool me. I am holding.

1 · Reply

revueltoL Oct. 3 at 3:07 AM

$EVAX of all the deeply discounted biotech tickers I hold, this one sits at the top…just a couple of weeks and it should settle into its true trading range…extremely bullish…

0 · Reply

HouseOfTheDragons Oct. 3 at 2:58 AM

Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $EVAX $BYON $IBO $APPS md

0 · Reply

Market Cap	2.30M
Revenue (ttm)	3.34M
Net Income (ttm)	-10.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-316.47%
Debt to Equity Ratio	-4.95

Volume	57,600
Avg Vol	68,002
Day's Range	N/A - N/A
Shares Out	1.40M
Stochastic %K	76%
Beta	-0.24
Analysts	Strong Sell
Price Target	$13.25